The message is concise: the FDA has placed a clinical hold on the IND. Or: the FDA has requested additional safety information. Or: new safety data requires immediate notification to all investigators.

What happens next at your site depends on two things. First, whether you have a response protocol that tells you exactly what to do, in what order, and by whom. Second, whether you understand where your coordination authority ends and the principal investigator's decision-making authority begins. The RC who confuses these boundaries during a regulatory event creates problems that outlast the event itself.

This lesson is not about what clinical holds are. You already know that. This lesson is about what happens at your site when one arrives -- the operational coordination, the authority boundaries, the documentation trail, and the portfolio implications when a regulatory action on one study consumes the RC's attention at the expense of the other 14.

The message is concise: the FDA has placed a clinical hold on the IND. Or: the FDA has requested additional safety information. Or: new safety data requires immediate notification to all investigators.

What happens next at your site depends on two things. First, whether you have a response protocol that tells you exactly what to do, in what order, and by whom. Second, whether you understand where your coordination authority ends and the principal investigator's decision-making authority begins. The RC who confuses these boundaries during a regulatory event creates problems that outlast the event itself.

This lesson is not about what clinical holds are. You already know that. This lesson is about what happens at your site when one arrives -- the operational coordination, the authority boundaries, the documentation trail, and the portfolio implications when a regulatory action on one study consumes the RC's attention at the expense of the other 14.